Correction of structural damage associated with GABA-derived diabetic cardiomyopathy

Diabetes mellitus (DM) is currently considered a serious epidemic worldwide and is the leading cause of cardiovascular disease and mortality in patients with DM. Diabetic cardiomyopathy (DCM) in the absence of coronary heart disease, heart defects, arterial hypertension, etc. is a multifactorial disease leading to ventricular hypertrophy, interstitial fibrotic changes in the heart and heart failure. Materials and methods. The modeling of diabetes was carried out for six months, after which treatment with succicard and aminalon 1000 mg/kg. The negative control group was administered physiological saline. After treatment, morphological changes in the heart were studied, heart weight, cardiomyocyte diameter and fibrosis severity in the left ventricular myocardium were measured. Results and discussion. The animals with DM showed the development of hypertrophy and fibrosis of the left ventricular (LV) myocardium. Age-related changes contributed to an increase in the severity of fibrosis. The use of succicard in DM demonstrated a pronounced protective effect, which was manifested by the restoration of morphometric parameters in the left ventricular myocardium and may be associated with the membrane and cardioprotective properties of succicard, aimed at normalizing metabolic processes in cardiomyocytes and protecting the vascular endothelium. Conclusions. The obtained data confirm the prospects of using succicard for the correction of morphological and functional myocardial disorders in diabetic cardiomyopathy, especially in conditions of comorbid conditions such as diabetes mellitus and aging.